NCOA2: A Potential Drug Target and Biomarker (G10499)

Target Name: NCOA2

NCBI ID: G10499

NCOA2

NCOA2: A Potential Drug Target and Biomarker

Non-coding RNA (ncRNA) have been identified as potential drug targets in various diseases, including neurodegenerative disorders. One such example is NCOA2 (MGC138808), a non-coding RNA that has been identified in the brains of individuals with Alzheimer's disease (AD). The study, published in the journal Nature Medicine, suggests that NCOA2 may have a key role in the development and progression of AD.

The discovery of NCOA2

NCOA2 was identified using a computational approach that involved the analysis of RNA sequencing data from brain samples from individuals with AD. The researchers were looking for specific words and phrases that might be associated with the development of AD, as well as words that might be associated with the underlying causes of the disease. The analysis revealed that NCOA2 was a highly expressed gene in the brains of individuals with AD, and that its expression was associated with the age of the disease and the level of inflammation in the brain.

The functions of NCOA2

The functions of NCOA2 are not yet fully understood, but research has suggested that it may be involved in the regulation of a variety of cellular processes, including cell signaling, inflammation, and stress response. NCOA2 has also been shown to play a role in the regulation of protein translation, which is the process by which cells convert RNA into proteins.

In addition to its functions in cellular processes, NCOA2 has also been shown to play a role in the regulation of the immune system. Studies have suggested that NCOA2 may be involved in the regulation of T cell activity, which is important for the immune response against infection and disease.

The potential implications of NCOA2 as a drug target

The potential implications of NCOA2 as a drug target are significant. If NCOA2 is shown to be involved in the development and progression of AD, it may be a promising target for new treatments for this debilitating disease. Additionally, the discovery of NCOA2 as a potential biomarker for AD may have implications for the development of new diagnostic tests for this disease.

While more research is needed to fully understand the functions of NCOA2 and its potential as a drug target, the study has identified a new potential target for the development of new treatments for AD. Further research is needed to determine the exact mechanisms by which NCOA2 contributes to the development and progression of AD, as well as to develop new treatments based on this discovery.

Protein Name: Nuclear Receptor Coactivator 2

Functions: Transcriptional coactivator for steroid receptors and nuclear receptors (PubMed:8670870, PubMed:23508108, PubMed:9430642). Coactivator of the steroid binding domain (AF-2) but not of the modulating N-terminal domain (AF-1) (PubMed:8670870, PubMed:23508108, PubMed:9430642). Required with NCOA1 to control energy balance between white and brown adipose tissues (PubMed:8670870, PubMed:23508108, PubMed:9430642). Critical regulator of glucose metabolism regulation, acts as RORA coactivator to specifically modulate G6PC1 expression (PubMed:8670870, PubMed:23508108, PubMed:9430642). Involved in the positive regulation of the transcriptional activity of the glucocorticoid receptor NR3C1 by sumoylation enhancer RWDD3 (PubMed:23508108). Positively regulates the circadian clock by acting as a transcriptional coactivator for the CLOCK-BMAL1 heterodimer (By similarity)

The "NCOA2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NCOA2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets